PepGen (PEPG) Competitors $5.08 +0.37 (+7.86%) Closing price 10/2/2025 04:00 PM EasternExtended Trading$5.03 -0.05 (-1.08%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. ANAB, PVLA, MGTX, SIGA, OLMA, KROS, BCAX, KALV, GOSS, and SNDLShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors AnaptysBio Palvella Therapeutics MeiraGTx Siga Technologies Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics KalVista Pharmaceuticals Gossamer Bio SNDL AnaptysBio (NASDAQ:ANAB) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Which has stronger earnings & valuation, ANAB or PEPG? PepGen has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M9.61-$145.23M-$4.48-7.00PepGenN/AN/A-$89.98M-$2.96-1.72 Does the media prefer ANAB or PEPG? In the previous week, AnaptysBio had 7 more articles in the media than PepGen. MarketBeat recorded 36 mentions for AnaptysBio and 29 mentions for PepGen. PepGen's average media sentiment score of 0.74 beat AnaptysBio's score of 0.43 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 6 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ANAB or PEPG? 58.0% of PepGen shares are held by institutional investors. 33.5% of AnaptysBio shares are held by company insiders. Comparatively, 5.2% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ANAB or PEPG? AnaptysBio has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, PepGen has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Is ANAB or PEPG more profitable? PepGen has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. PepGen's return on equity of -92.51% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% PepGen N/A -92.51%-70.39% Do analysts rate ANAB or PEPG? AnaptysBio currently has a consensus target price of $48.75, suggesting a potential upside of 55.55%. PepGen has a consensus target price of $8.40, suggesting a potential upside of 65.35%. Given PepGen's higher probable upside, analysts plainly believe PepGen is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80PepGen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryPepGen beats AnaptysBio on 9 of the 16 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.49M$3.31B$6.03B$10.52BDividend YieldN/A2.29%5.68%4.67%P/E Ratio-1.7221.5976.5526.55Price / SalesN/A260.59504.31202.22Price / CashN/A46.3737.8961.20Price / Book1.409.8412.456.48Net Income-$89.98M-$52.59M$3.30B$277.02M7 Day Performance0.20%3.90%28,070.60%1.68%1 Month Performance326.89%11.19%29,008.33%8.37%1 Year Performance-43.56%27.67%35,794.64%30.89% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen3.7689 of 5 stars$5.08+7.9%$8.40+65.4%-43.8%$154.49MN/A-1.7230Trending NewsInsider TradeAnalyst RevisionANABAnaptysBio2.6364 of 5 stars$23.27-1.3%$46.13+98.2%-10.5%$660.17M$91.28M-5.19100Trending NewsAnalyst ForecastAnalyst RevisionPVLAPalvella Therapeutics2.9255 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AAnalyst ForecastMGTXMeiraGTx4.302 of 5 stars$8.25+0.9%$24.00+190.9%+98.6%$658.06M$33.28M-4.04300Positive NewsSIGASiga Technologies1.8831 of 5 stars$8.96-2.2%N/A+29.3%$655.91M$138.72M7.9340News CoveragePositive NewsOptions VolumeOLMAOlema Pharmaceuticals3.1354 of 5 stars$9.54+0.3%$24.00+151.6%-7.6%$652.71MN/A-4.8270KROSKeros Therapeutics2.6249 of 5 stars$15.95-0.6%$30.00+88.1%-74.6%$651.88M$3.55M51.45100BCAXBicara Therapeutics1.987 of 5 stars$13.87+18.4%$32.25+132.5%-28.0%$638.93MN/A-4.3832High Trading VolumeKALVKalVista Pharmaceuticals3.9502 of 5 stars$12.21-1.5%$26.43+116.5%-0.8%$626.49MN/A-3.10100GOSSGossamer Bio3.9338 of 5 stars$2.82+4.4%$8.50+201.4%+136.2%$613.93M$114.70M-4.55180SNDLSNDL3.5899 of 5 stars$2.74+17.6%$4.50+64.2%+27.8%$612.27M$671.81M-10.152,516High Trading Volume Related Companies and Tools Related Companies AnaptysBio Alternatives Palvella Therapeutics Alternatives MeiraGTx Alternatives Siga Technologies Alternatives Olema Pharmaceuticals Alternatives Keros Therapeutics Alternatives Bicara Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Gossamer Bio Alternatives SNDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
